Authors' reply to 'RE: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group'. - Nishina T; Boku N; Kurokawa Y; Sasaki K; Machida R; Yoshikawa T (Japanese journal of clinical oncology, 2025)